LeveyA.S., BetoJ.A., CoronadoB.E., EknoyanG., FoleyR.N., KasiskeB.L.Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.Am J Kidney Dis1998; 32: 853–906.
2.
IkonomidisI., AndreottiF., EconomouE., StefanadisC., ToutouzasP., NihoyannopoulosP.Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.Circulation1999; 100: 793–8.
3.
PernerstorferT., EichlerH.G., StohlawetzP., SpeiserW., JilmaB.Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men.Atherosclerosis2001; 155: 389–93.
4.
de WinterR.J.C-Reactive protein and cardiac troponin for early risk stratification in patients with acute coronary syndromes.Clin Chim Acta2001; 311: 53–6.
5.
KennonS., PriceC.P., MillsP.G., RanjadayalanK., CooperJ., ClarkeH.The effect of aspirin on C-reactive protein as a marker of risk in unstable angina.J Am Coll Cardiol2001; 37: 1266–70.
6.
FengD., TracyR.P., LipinskaI., MurilloJ., McKennaC., ToflerG.H.Effect of short-term aspirin use on C-reactive protein.J Thromb Thrombolysis2000; 9: 37–41.
7.
FeldmanM., JialalI., DevarajS., CryerB.Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo-controlled study using a highly sensitive C-reactive protein assay.J Am Coll Cardiol2001; 37: 2036–41.
